{
    "clinical_study": {
        "@rank": "143004", 
        "arm_group": [
            {
                "arm_group_label": "SER100", 
                "arm_group_type": "Experimental", 
                "description": "SER100 10 mg s.c. twice daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered s.c. twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly\n      people. Much attention has recently been drawn to the strong relationship between the\n      systolic blood pressure and cardiovascular morbidity.\n\n      In previous clinical studies carried out in individuals with normal blood pressure at\n      baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the\n      effect on systolic blood pressure in hypertensive patients will be larger or equal to the\n      fall seen in normotensive patients."
        }, 
        "brief_title": "SER100 in Isolated Systolic Hypertension", 
        "condition": "Isolated Systolic Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Mean systolic blood pressure \u2265 150 mmHg and mean diastolic blood pressure < 90 mmHg -\n             as determined by daytime continuous ambulatory blood pressure measurement (ABPM)\n\n          -  Male or female\n\n          -  Age 50-80 years (both inclusive) at screening\n\n          -  Patients must be on stable doses with one or more antihypertensives\n\n          -  BMI <32 kg/m2\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Acute myocardial infarction in the last 6 months before screening\n\n          -  Stroke in the last 6 months before screening\n\n          -  Uncompensated heart failure (NYHA Class IV)\n\n          -  Angina pectoris with an anticipated need for administration of short-acting nitrates\n\n          -  Known, severe sleep apnoea\n\n          -  Abnormal laboratory values (i.e. > 2 x upper normal limit) at screening\n\n          -  Subjects working night shifts (11 PM to 7 AM)\n\n          -  Participation in any other clinical trial with an investigational medicinal product\n             or device within 1 month prior to randomisation.\n\n          -  Subjects with upper arm circumference \u226424 cm or  \u2265 42 cm.\n\n          -  Any general condition, serious disease or current evidence of any mental or physical\n             disorder or collaboration attitude (e.g. dementia, substance abuse) which, in the\n             judgment of the investigator makes the subject unsuitable for enrollment, and/or may\n             interfere with the study evaluations or affect subject's safety and/or may cause risk\n             for poor protocol compliance\n\n          -  Pregnant or lactating women.\n\n          -  Female subjects of childbearing potential, or male subjects  whose female partner\n             (unless post-menopausal for 1 year or surgically sterile) is unwilling to use\n             adequate contraceptive measures throughout the duration of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987284", 
            "org_study_id": "SMR-2271", 
            "secondary_id": "2013-001227-40"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SER100", 
                    "Placebo"
                ], 
                "intervention_name": "SER100", 
                "intervention_type": "Drug", 
                "other_name": "N.A."
            }, 
            {
                "arm_group_label": [
                    "SER100", 
                    "Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antihypertensive Agents"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Juha Alanko, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland"
                    }, 
                    "name": "FinnMedi Oy/Valkeakoski District Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ilkka Kantola, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland"
                    }, 
                    "name": "CRST/Turku University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Judit Kaposci, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Semmelweiss University Hospital"
                }, 
                "investigator": {
                    "last_name": "Judit Kapocsi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hans Hoivik, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Hamar", 
                        "country": "Norway", 
                        "zip": "2317"
                    }, 
                    "name": "Medi3 Innlandet"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helga Gudmundsdottir, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0450"
                    }, 
                    "name": "Ulleval University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harrow", 
                        "country": "United Kingdom", 
                        "state": "Middlesex", 
                        "zip": "HA1 3UJ"
                    }, 
                    "name": "Northwick Park Hospital"
                }, 
                "investigator": {
                    "last_name": "Roxy Senior, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Okorie, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Brighton", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Brighton and Sussex University Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Finland", 
                "Hungary", 
                "Norway", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.", 
        "overall_contact": {
            "email": "oivind.foss@smerud.com", 
            "last_name": "\u00d8ivind Foss, M.Sc.", 
            "phone": "+472327", 
            "phone_ext": "2000"
        }, 
        "overall_official": {
            "affiliation": "Oslo University Hospital", 
            "last_name": "Helga Gudmundsdottir, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Norway: Norwegian Medicines Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Finland: Finnish Medicines Agency", 
                "Hungary: National Institute of Pharmacy"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987284"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from baseline in systolic blood pressure", 
            "safety_issue": "No", 
            "time_frame": "Up to 4 weeks"
        }, 
        "source": "Serodus ASA", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Smerud Medical Research International AS", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Research Council of Norway", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Serodus ASA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}